After landing astronauts on the moon in the mid-2020s for the first time in more than a half-century, NASA will wait at least two more years before making a second crewed lunar landing as part of the Artemis program.
The pandemic has been challenging for the industry, with agents and consumers navigating a wily housing market and the difficulties of pandemic life. To honor agents' tenacity, RE/MAX has a new ad campaign, "The Right Agent Can Lead the Way."
In a little over six weeks on the 1st March, Athens will host the Greece Gambling Conference 2022 dedicated to various aspects of the gambling business in Greece, the prospects for development of the gambling market in the country and the specifics of its legislative regulation. Situated in the Novotel Athens hotel with a fantastic […]
Proposals are invited for sessions at International Data Week’s SciDataCon 2022: Data to Improve our World. The deadline for proposals is 23:59 UTC on 14 February 2022. Submit your session proposal at https://www.scidatacon.org/IDW-2022/submit/ About SciDataCon 2022 and International Data Week 2022 SciDataCon 2022 is part of International Data Week 2022, to be held virtually and in Seoul, […]
The number of new clinical trials for medical devices in December 2021 saw a 23% decrease globally when compared with the last 12-month average, according to GlobalData’s medical devices clinical trials database. The global medical devices market was worth $479.97bn in 2020 and is expected to reach $532.37bn by 2023, according to GlobalData’s analysis. Medical …
The number of planned and ongoing clinical trials (new) for medical devices in December 2021 saw a decrease 19% globally when compared with the last 12-month average, according to GlobalData’s medical devices clinical trials database. The global medical devices market was worth $479.97bn in 2020 and is expected to reach $532.37bn by 2023, according to …
The focus of this article is on data democratization within the business enterprise, but the concepts and approaches involved in implementing this type of initiative are worth considering for any kind of major change within an organization. When thinking about business environments – how they are established and how they evolve – it is often […]
TOKYO, Jan 17, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI22), taking place in-person in San Francisco, California, and virtually, from January 20 to 22, 2022.
At this symposium, the results of a primary analysis of a prospective clinical study evaluating transcatheter arterial chemoembolization (TACE) therapy in combination strategy with lenvatinib (TACTICS-L) in patients with unresectable hepatocellular carcinoma (uHCC) in Japan (Abstract No: 417), as well as research updates on the Phase IV Study (STELLAR) to evaluate safety and tolerability of lenvatinib in patients with advanced/unresectable hepatocellular carcinoma (Abstract No: TPS485) and results from a clinical study to evaluate the efficacy of lenvatinib for conversion surgery in patients with uHCC (investigator-initiated study in Japan, Abstract No: 458), will be presented.
In addition, trial-in-progress (TiP) posters from the clinical program evaluating the combination therapy of lenvatinib plus pembrolizumab (product name: KEYTRUDA), the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada), include the Phase III LEAP-014 Study of the combination plus chemotherapy in patients with esophageal carcinoma squamous cell carcinoma (Abstract No: TPS367), Phase III LEAP-015 Study of the combination plus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma (Abstract No: TPS369), Phase III Study LEAP-012 of the combination plus TACE in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment (Abstract No: TPS494), and Phase II Study of the combination plus belzutifan in patients with advanced solid tumors (Abstract No: TPS669).
In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.
Eisai positions oncology as a key therapeutic area and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.
This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
About the Merck & Co., Inc., Kenilworth, N.J., U.S.A. and Eisai Strategic Collaboration
In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A.
In addition to ongoing clinical studies evaluating the LENVIMA plus KEYTRUDA combination across several different tumor types, the companies have jointly initiated new clinical studies through the LEAP (LEnvatinib And Pembrolizumab) clinical program and are evaluating the combination in more than 10 different tumor types across more than 20 clinical trials.
Eisai's Focus on Cancer
Eisai focuses on the development of anticancer drugs, targeting the tumor microenvironment (with experience and knowledge from existing in-house discovered compounds) and the driver gene mutation and aberrant splicing (leveraging RNA Splicing Platform) as areas (Ricchi) where real patient needs are still unmet, and where Eisai can aim to become a frontrunner in oncology. Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these Ricchi, with the aim of contributing to the cure of cancers.
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.
Media Inquiries: Public Relations Department, Eisai Co., Ltd. +81-(0)3-3817-5120
Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, 'lenvatinib") will be given at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI22), taking place in-person in San Francisco, California, and virtually, from January 20 to 22, 2022.
Any modern company of any significant size around the world has a data science department, and a data engineer at one company might have the same responsibilities as a marketing scientist at another company. Data science jobs are not well-labeled, so make sure to cast a wide net.
When Apple finally released its M1 Max processor in October, the Internet predictably saw dark days for PC laptops. Some even felt bad for PC laptop makers being uncompetitive with the MacBook Pro for perhaps “years.” Those predictions may have to be retuned a bit now that Intel and Nvidia have both come out swinging at Apple, however.
Nvidia was the first to step on Apple's sneakers when it announced its new GeForce RTX 3070 Ti and GeForce RTX 3080 Ti Laptop GPUs. Nvidia casually compared not just its newest GeForce RTX 3080 Ti Laptop GPU against Apple's fastest M1 Max, but also the far more pedestrian GeForce RTX 3060 Laptop GPU using Autodesk Arnold, Blender, Chaos V-Ray, OctaneRender and Redshift.
As you can see from the comparison with the MacBook Pro 16's M1 Max, both the new GeForce flagship and the far blander RTX 3060 Laptop GPU simply crush the M1 Max. And by crush, we mean crush, because when a GeForce RTX 3080 Ti Laptop GPU takes 10 minutes to perform a render and a GeForce RTX 3060 Laptop GPU takes 22 minutes using Autodesk Arnold, versus 78 minutes for the M1 Max, it's a beat-down. That's an 87 percent decrease in rendering time for the RTX 3080 Ti vs. the M1 Max, and a 78 percent advantage for the RTX 3060. That's a shellacking no matter how you count it for working creators, but it should be pointed out that many of these apps have long been optimized for Nvidia's GPUs, giving GeForce a home field advantage.
Nvidia
For example, it's not clear if the testing Nvidia did for Blender Cycles used the version that's currently being ported to Apple's M1 and Metal API. We'd guess not since the presentation would have been based on numbers likely prepared well before CES 2022 to meet approval for public dissemination. With Blender support still in pre-beta stage, it's highly doubtful the Blender score is running an alpha version.
So is it fair if Nvidia shows off a stack of benchmarks arguably optimized for its GPU versus the unknown quantity of M1 Max support? It depends.
If your idea of a good time is to get into a yelling match on Twitter while wearing an Apple team jersey over the “unfairness” of Nvidia's results, then it's definitely not fair. If you're a working professional who gets paid to shovel pixels in Autodesk Arnold, Blender, V-Ray, OctaneRender, or Redshift, then it's most certainly a fair test, since the only thing you probably care about is how fast your hardware can make you money.
Intel steps up too
After Nvidia poked Apple in the nose a few times, Intel jumped into the ring later that morning by saying that its new 12th-gen “Alder Lake” laptop CPUs are faster than not only its older 11th-gen Tiger Lake H CPUs and AMD's Ryzen 9 5900HX, but also Apple's M1 Max. So yes, as the slide below says, the fastest mobile processor. Ever.
Intel
What's that based on? Fortunately, responsible companies show their homework as Intel did. In fact, Intel shows way more of its work than Nvidia did in its video, which publishes the results, but no information about how it tested the laptops.
Intel says its performance results for the Apple M1 Max is estimated based on: “public statements made by Apple on 10/18/2021 and measurements on Apple M1 Max 16″ 64GB RAM Model A2485. The metric used is the geometric mean of an n-copy SPECrate run of the C/C++ integer benchmarks in SPEC CPU 2017.”
For the uninitiated, SPEC is published by Standard Performance Evaluation Corporation, an industry group that has come together to create various agreed-upon tests and proclaims itself a “beacon of truth for 30 years.” Members include a who's who of tech companies including AMD, Apple, Intel, and Nvidia. You're typically required to publish much of the fine print, including wh
at was used to compile the executables for the test too.
In Intel's case, it said it used ICC for the Windows laptops and Apple's Xcode 13.1 for the M1 Max. To its credit (although some would say it's just to avoid further Imperial entanglements), Intel discloses far more details on how it achieved its claim here.
Intel
Still, the upshot of Intel's tests says that even at 28 watts or so of power consumption, it's easily outperforming the M1 Max in a test even Apple has signed onto. As you push the wattage envelope of the Core i9-12900HK you're looking at perhaps near 45 percent more performance than that M1 Max.
So, what should you believe? One problem with SPEC benchmarks, though sometimes based on actual application code, is the lack of relatability for consumers. They can be useful for computer science students arguing in the quad, but for most people they're pretty esoteric. We'd probably want to see something we can relate to before determining if and how much of a beat down the new 12th-gen Alder Lake gives the M1 Max. It's very hard to argue against a test published by a benchmarking group even Apple is a member of though.
And it's good Intel published its homework. We wish Nvidia would have said a little more about how it tested the laptops against the Apple M1 Max—did the workloads include ray tracing features that GeForce GPUs pack dedicated hardware for? But it's hard to complain about what Nvidia did when Apple has been publishing results like the one below. This is a benchmark result Apple showed off for the M1 Max's launch and, frankly, we still have no idea what Apple based it on. The dark gray line represents MSI's killer GE76 Raider gaming laptop that's actually—to Apple's credit—displayed as being faster than the M1 Max. The lighter gray line is a Razer Blade Advanced, which is slightly slower than the M1 Max. Both are outfitted with a GeForce RTX 3080 Laptop GPUs.
Apple
The M1 Max may lose or come close to Nvidia's GPUs in raw performance, but Apple's real victory is its power consumption. Apple's M1 Max and its TSMC 5nm process is indeed impressive for the power it consumes. At the same time, just what the hell was Apple testing? We have no doubt the M1 Max is indeed efficient, but of the three “our bars are longer” presentations, Apple's is the thinnest on actual details and mostly leaves you wondering just how it determined what it did. If you're concerned over Nvidia or Intel being fair, you should be even more concerned about Apple's claims.
In the end, consumers should always take any vendor's claims with a grain of salt. Wait for independent reviews using tests that relate to what you actually do with your laptop before deciding what to buy.